Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). (Q37922775)

25 August 2017

1 reference

title

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Michael B Jameson

1

1 reference

25 August 2017

Michelle Head

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

26 August 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1315-1326

1 reference

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Vascular-targeting therapies for treatment of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.614389

10.1517/17425255.2011.614389

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference